Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Clin Immunol ; 264: 110263, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38795901

ABSTRACT

BACKGROUND: Hematopoietic stem cell transplantation (HSCT) is a curative treatment for certain inborn errors of immunity. METHODS: A 17-year retrospective cohort study was conducted on 40 immunodeficient patients who underwent HSCT. RESULTS: The median age at transplant was 11.0 months (4.6-61.0). Donors were primarily matched sibling donors (60%). 90% and 85% of patients received conditioning and graft-versus-host disease (GVHD) prophylaxis, respectively. The mean donor chimerism at the last follow-up was 88.6% ± 17.9% (40-100). Median serum immunoglobulin (Ig) G level, CD4+ T-cell count, and CD19+ B-cell count were 11.7 g/L (9.2-13.6), 0.9 × 109/L 0.6-1.2), and 0.5 × 109/L (0.2-0.7), respectively. 29 patients (72.5%) received intravenous immunoglobulins (IVIG) therapy, with a median duration of 10.0 months (4.0-14.0). The median post-transplant follow-up was 6.5 years (IQR:1.4-11.5). The 10-year overall probability of survival is 84.3%. CONCLUSION: Monitoring IRC is important in ensuring adequate disease-free survival.


Subject(s)
Graft vs Host Disease , Hematopoietic Stem Cell Transplantation , Immune Reconstitution , Humans , Hematopoietic Stem Cell Transplantation/methods , Male , Female , Retrospective Studies , Infant , Graft vs Host Disease/immunology , Child, Preschool , Oman , Transplantation Conditioning/methods , Immunoglobulins, Intravenous/therapeutic use , Immunoglobulin G/blood , B-Lymphocytes/immunology
2.
Pediatr Blood Cancer ; 70(11): e30647, 2023 11.
Article in English | MEDLINE | ID: mdl-37638819

ABSTRACT

BACKGROUND: Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), recently known as nodular lymphocyte-predominant B-cell lymphoma (NLPBL), accounts for 5%-10% of Hodgkin lymphoma (HL). Different morphologic patterns of NLPBL are identified and categorized as typical patterns (type A and B) and variant histologic patterns (types C, D, E, and F). PATIENTS AND METHOD: We investigated different morphologic patterns, CD30 and IgD expression in pediatric patients with NLPBL diagnosed at the Children's Cancer Hospital Egypt. RESULTS: Forty-six (53%) of the patients exhibited a typical histologic pattern, whereas the remaining (47%) exhibited variant histologic pattern. Variant histology is associated with unfavorable clinical characteristics, such as advanced stages, B-symptoms, and extranodal involvements, particularly bone marrow and bone infiltration, with p-values of .06, .05, and 0.01%, respectively. Additionally, 39% of patients with variant histology experienced disease progression or relapse, compared to only 15.2% of patients with typical patterns (p = .009). Types C and D are related to decreased event-free survival (EFS), as shown by a p-value of .05. The 5-year EFS for patients with variant histology was 94.4% for the rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone (RCHOP) versus 33.3% for the adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD). IgD expression in lymphocyte-predominant (LP) cells was detected in 44 (50%) patients, while CD30 expression in LP cells was found in 39 (44%) patients. CONCLUSION: Variant histology of NLPBL was associated with advanced disease stages and a poor prognosis, while expression of IgD and CD30 in LP cells was not. The poor outcome of variant histology improved with the RCHOP regimen.


Subject(s)
Hodgkin Disease , Lymphoma, Follicular , Humans , Child , Hodgkin Disease/drug therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Doxorubicin , Bleomycin , Dacarbazine , Vinblastine , Neoplasm Recurrence, Local , B-Lymphocytes
3.
Cureus ; 15(6): e40215, 2023 Jun.
Article in English | MEDLINE | ID: mdl-37435251

ABSTRACT

Calcineurin inhibitors (CNI) are the mainstay of immunosuppressant medications in both bone marrow transplants and solid organ transplants. Nephrotoxicity is a well-known adverse effect of this group. Type IV renal tubular acidosis is a potentially under-recognized complication. Here we report a case of Omenn syndrome in a patient who underwent a bone marrow transplant and developed type IV renal tubular acidosis while on treatment with cyclosporine.

4.
Int J Cancer ; 148(7): 1562-1574, 2021 04 01.
Article in English | MEDLINE | ID: mdl-32997796

ABSTRACT

Childhood cancer is a priority in Egypt due to large numbers of children with cancer, suboptimal care and insufficient resources. It is difficult to evaluate progress in survival because of paucity of data in National Cancer Registry. In this study, we studied survival rates and trends in survival of the largest available cohort of children with cancer (n = 15 779, aged 0-18 years) from Egypt between 2007 and 2017, treated at Children's Cancer Hospital Egypt-(CCHE), representing 40% to 50% of all childhood cancers across Egypt. We estimated 5-year overall survival (OS) for 14 808 eligible patients using Kaplan-Meier method, and determined survival trends using Cox regression by single year of diagnosis and by diagnosis periods. We compared age-standardized rates to international benchmarks in England and the United States, identified cancers with inferior survival and provided recommendations for improvement. Five-year OS was 72.1% (95% CI 71.3-72.9) for all cancers combined, and survival trends increased significantly by single year of diagnosis (P < .001) and by calendar periods from 69.6% to 74.2% (P < .0001) between 2007-2012 and 2013-2017. Survival trends improved significantly for leukemias, lymphomas, CNS tumors, neuroblastoma, hepatoblastoma and Ewing Sarcoma. Survival was significantly lower by 9% and 11.2% (P < .001) than England and the United States, respectively. Significantly inferior survival was observed for the majority of cancers. Although survival trends are improving for childhood cancers in Egypt/CCHE, survival is still inferior in high-income countries. We provide evidence-based recommendations to improve survival in Egypt by reflecting on current obstacles in care, with further implications on practice and policy.


Subject(s)
Neoplasms/mortality , Adolescent , Cancer Care Facilities , Central Nervous System Neoplasms/mortality , Child , Child, Preschool , Cohort Studies , Egypt , England , Female , Hepatoblastoma/mortality , Humans , Infant , Infant, Newborn , Kaplan-Meier Estimate , Leukemia/mortality , Lymphoma/mortality , Male , Neuroblastoma/mortality , Regression Analysis , Retrospective Studies , Sarcoma, Ewing/mortality , United States
5.
Clin Lymphoma Myeloma Leuk ; 20(7): e368-e374, 2020 07.
Article in English | MEDLINE | ID: mdl-32209330

ABSTRACT

INTRODUCTION: Juvenile myelomonocytic leukemia (JMML) is a rare clonal myelodysplastic/myeloproliferative neoplasm of early childhood. Historically, it was difficult to diagnose clinically, as patients present with manifestations shared with other hematologic malignancies or viral infections. It is now clear that JMML is a disease of hyperactive RAS signaling. PATIENTS AND METHODS: We examined the bone marrow of 41 Egyptian children with JMML by direct sequencing for mutations in the RAS pathway genes. RESULTS: Mutations were detected in 33 (80%) of 41 patients. We identified 12 (29%) of 41 patients with PTPN11 mutation; 18 (44%) of 41 with RAS mutation; 9 (22%) of 41 with NRAS mutation; 9 (22%) of 41 with KRAS mutation; and 3 (7%) of 41 with CBL mutation. Eleven (92%) of the PTPN11 mutations were detected in exon 3 and 1 (8%) in exon 13. Seven of the NRAS mutations were in exon 2, and 2 were in exon 3. All KRAS mutations were in exon 2. The 3 cases with CBL mutation were homozygous mutations in exon 8. All the mutations detected in PTPN11, NRAS/KRAS, and the CBL genes were previously reported missense mutations in JMML. CONCLUSION: Our results demonstrate that Egyptian children diagnosed with JMML have high frequency of NRAS/KRAS mutations and lower frequency of PTPN11 mutations as compared with previous studies. The concept of mutually exclusive RAS pathway mutations was clearly observed in our patients. All cancer centers in our region should start implementing molecular diagnostic methods before confirming the diagnosis of JMML and before offering hematopoietic stem cell transplantation.


Subject(s)
Genes, ras/genetics , Leukemia, Myelomonocytic, Juvenile/genetics , Child, Preschool , Developing Countries , Egypt , Female , Humans , Infant , Leukemia, Myelomonocytic, Juvenile/pathology , Male , Mutation , Signal Transduction
6.
J Endod ; 46(5): 563-574, 2020 May.
Article in English | MEDLINE | ID: mdl-32173020

ABSTRACT

INTRODUCTION: The present study quantitatively assessed tissue regeneration after regenerative endodontic procedures (REPs) with 2 different apical preparation sizes in mature teeth using magnetic resonance imaging (MRI). METHODS: Eighteen maxillary anterior mature necrotic teeth with periapical lesions were selected for the study. The teeth were randomly allocated into 2 groups. Canal preparation was performed using Protaper Next files (Dentsply Sirona, York, PA) until size X3 and X5 in the test and control groups, respectively. REPs were performed, and Biodentine (Septodont, Saint-Maur-des-Fossés, France) was used as the cervical plug material. In both groups, MRI was used to measure the signal intensity (SI) of the regenerated tissue at 3, 6, and 12 months at both the middle and the apical thirds of the canal. The SI between the normal contralateral teeth and each successive interval was compared. Clinical examination, sensibility tests, and digital periapical radiographs were also performed at successive time intervals. Statistical analysis was performed using the Student t test and Cochran test. The level of significance was set at P ≤ .05. RESULTS: All 18 teeth were symptom free with healing of the periapical lesions. Regarding the SI measurements, there was no statistically significant difference between the SI of the normal contralateral teeth and that of the regenerated tissues in the treated teeth after a 12-month follow-up. In both groups, more than 60% of the cases regained pulp sensibility after 12 months. CONCLUSIONS: Vital pulplike tissue could be successfully regenerated in mature teeth using REPs, which was not significantly affected by the size of the apical diameter. MRI could successfully assess this tissue in a quantitative, noninvasive manner.


Subject(s)
Periapical Periodontitis , Regenerative Endodontics , Dental Pulp Necrosis , France , Humans , Magnetic Resonance Spectroscopy , Root Canal Therapy
7.
Pediatr Transplant ; 23(6): e13531, 2019 09.
Article in English | MEDLINE | ID: mdl-31271483

ABSTRACT

BACKGROUND: Children and adolescents with HL have excellent long-term survival exceeding 95% after combined modality treatment. However, about 20% will either relapse or have PRF. Salvage HDCT followed by AHSCT is considered to be the preferential treatment. OBJECTIVE: To describe the outcome (OS and EFS) and prognostic factors in pediatric patients with relapsed or refractory HL (r/rHL) who underwent AHSCT. METHODS: We retrospectively included 43 pediatric patients with r/rHL who underwent AHSCT from July 1, 2007, till December 31, 2016, at the Children's Cancer Hospital of Egypt. MAC regimen given was CMV. RESULTS: Of the whole cohort, 88.4% of patients achieved CR, while 11.6% had a positive PET scan prior to transplantation. The 3-year OS and EFS were 85% and 70.6%, respectively. The 3-year OS for patients > 10 years was 94% versus 65.5% for patients 10 years of age or younger (P = 0.046). There is strong tendency toward better 3-year OS for patients with negative PET scan as compared to those with positive PET scan before AHSCT, 89.4% vs 60%, respectively (P = 0.059). This tendency is also applicable when looking at the 3-year EFS for the two groups, 78.3% vs 40%, respectively (P = 0.069). CONCLUSION: Poor predictors of OS were younger age and positive PET scan before AHSCT. The latter, along with single modality treatment before AHSCT, were poor predictors of EFS.


Subject(s)
Hematopoietic Stem Cell Transplantation , Hodgkin Disease/therapy , Adolescent , Child , Child, Preschool , Combined Modality Therapy , Egypt , Female , Humans , Male , Neoplasm Recurrence, Local , Positron-Emission Tomography , Prognosis , Recurrence , Retrospective Studies , Salvage Therapy , Transplantation, Autologous , Treatment Outcome , Young Adult
8.
Clin Lymphoma Myeloma Leuk ; 19(5): e221-e227, 2019 05.
Article in English | MEDLINE | ID: mdl-30846344

ABSTRACT

INTRODUCTION: Recovery of platelet count by day 100 after hematopoietic stem-cell transplantation (HSCT) is affected by many factors and has been reported to be a predictor of overall survival (OS) in a variety of diseases and donor types. We investigated the correlation between day +100 platelet count and OS after allogeneic HSCT in a relatively homogeneous cohort of pediatric patients with hematologic malignancies. PATIENTS AND METHODS: We conducted a retrospective study of 152 consecutive patients who underwent allogeneic HSCT at the Children's Cancer Hospital Egypt between 2009 and 2015 with a minimum follow-up duration of 1 year after transplantation. All eligible patients received myeloablative conditioning, and all had matched related donors. Patients who survived without relapse until day 100 after HSCT were divided into 2 groups: early platelet recovery (EPR; platelet count ≥ 100 × 109/L at day +100 after transplantation) and delayed platelet recovery (DPR; platelet count < 100 × 109/L at day +100 after transplantation). RESULTS: At day +100, 113 patients (74%) had EPR and 39 patients (26%) had DPR. With a median follow-up of 41 months (range, 12-93 months), 41 patients (27.2%) died, 35 of relapsed disease. The 3-year disease-free survival (DFS) and OS were 68 ± 7.84% and 71.9 ± 7.84%, respectively. The 3-year OS was 77.9% in the EPR group and 57.1% in the DPR group (P = .006). Three-year DFS of the EPR and DPR groups were 73.2 ± 9% and 54.8 ± 16.3%, respectively (P = .02). Incidence of disease relapse for EPR and DPR patients was 22.6% and 39.5%, respectively (P = .04). Multivariate analysis for survival identified DPR as a predictor of decreased survival (P = .002). CONCLUSION: Patients with a robust platelet count at day 100 are likely to do well. However, patients who do not experience a platelet count of ≥ 100 × 109/L have inferior long-term OS and DFS and may require further evaluation at the day 100 time point.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Blood Platelets , Hematologic Neoplasms/therapy , Hematopoietic Stem Cell Transplantation , Myeloablative Agonists/administration & dosage , Adolescent , Child , Child, Preschool , Disease-Free Survival , Female , Follow-Up Studies , Hematologic Neoplasms/blood , Hematologic Neoplasms/mortality , Humans , Infant , Kaplan-Meier Estimate , Male , Platelet Count/methods , Postoperative Period , Retrospective Studies , Time Factors , Transplantation Conditioning/methods , Transplantation, Homologous , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...